BusinessCicloMed Announces Presentation of Preclinical Evidence for its Bladder Cancer Agent at AACR 2018 MeetingBy Nasdaq OMXApr 12, 2018, 1:01 PM UTC
BusinessCicloMed Announces First Patient Dosed with Ciclopirox Prodrug in Phase I Trial in Patients with Advanced Solid TumorsBy Nasdaq OMXFeb 28, 2018, 3:08 PM UTC
BusinessCicloMed Announces FDA Clearance of IND Application for Ciclopirox Prodrug in the Treatment of Bladder CancerBy Nasdaq OMXOct 11, 2017, 1:00 PM UTC
